Drugs / MT-304
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07334119 | Nov 2025 → Jan 2027 expected | carcinoma | Myeloid Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-304 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07334119 ↗ |
| Route | Intravenous | “Participants receive MT-304 administered intravenously once every 14 days (Q14D)” NCT07334119 ↗ |